Urine Peptide Test Accurately Detects Early Diabetic Kidney Disease Across Multiple Hospitals
A urine test measuring 273 peptide fragments (CKD273) achieved near-perfect accuracy for detecting diabetic kidney disease progression across 9 hospitals, regardless of patient age or gender.
Quick Facts
What This Study Found
A urinary peptide-based diagnostic test called CKD273 — which measures 273 peptide fragments in urine — was validated across 9 different medical centers with remarkable consistency. The test achieved areas under the curve (AUC) of 0.95 to 1.00 for detecting diabetic nephropathy progression in type 2 diabetes patients, meaning it was nearly perfect at distinguishing those whose kidney disease would progress.
The classifier worked reliably regardless of patient age (16-89 years), gender, or what type of container was used to collect the urine. The most consistently detected peptides came from blood-derived and extracellular matrix proteins, suggesting these are the most robust biomarkers for kidney damage in diabetes.
Key Numbers
n=165 · 9 centers · 273 urinary peptides measured · AUC 0.95-1.00 · Age range tested: 16-89 years · Independent of gender and sample container type
How They Did This
Prospective multicentre validation study within the PRIORITY trial. 165 type 2 diabetes patients provided urine samples across 9 different institutions. Samples were analyzed using the CKD273 urinary proteomics classifier, which measures 273 specific peptide fragments using capillary electrophoresis coupled with mass spectrometry. Researchers tested consistency across centers and evaluated whether age, gender, or sample storage containers affected results.
Why This Research Matters
Diabetic kidney disease (nephropathy) is one of the most devastating complications of type 2 diabetes and the leading cause of kidney failure worldwide. Current detection methods often catch the disease too late for effective intervention. A urine test that can predict kidney disease progression before significant damage occurs could allow earlier treatment and potentially prevent kidney failure. The fact that CKD273 works consistently across multiple centers and is unaffected by age, gender, or sample handling makes it practical for real-world clinical use.
The Bigger Picture
This study represents a major step toward precision diagnostics for diabetic kidney disease. Traditional tests like microalbuminuria have significant limitations — many patients progress to kidney failure despite normal albumin levels. Peptide-based urine diagnostics could enable a new paradigm of early detection and intervention, potentially preventing millions of people with diabetes from developing kidney failure. The CKD273 test is part of a broader trend toward using proteomics and peptidomics as clinical diagnostic tools.
What This Study Doesn't Tell Us
Sample size of 165 is moderate for a validation study. This is a validation of the classifier's analytical consistency, not a long-term outcomes study proving it prevents kidney failure. The study was conducted within a specific trial population (PRIORITY trial participants), which may not fully represent all type 2 diabetes patients. Cost and accessibility of proteomics-based testing may limit widespread adoption.
Questions This Raises
- ?Can early detection with CKD273 actually change patient outcomes if intervention begins before traditional markers are abnormal?
- ?What would it cost to implement CKD273 testing in routine diabetes care, and would it be cost-effective compared to standard monitoring?
- ?Could a similar peptide-based approach work for detecting kidney disease from other causes beyond diabetes?
Trust & Context
- Key Stat:
- AUC 0.95-1.00 Near-perfect diagnostic accuracy for detecting diabetic kidney disease progression across all 9 participating medical centers
- Evidence Grade:
- This is a prospective multicentre validation study — a strong design for diagnostic test evaluation. The consistency across 9 centers strengthens confidence. However, it's a validation of analytical performance rather than proof of clinical outcome improvement, and the sample size is moderate.
- Study Age:
- Published in 2014. CKD273 has since been further validated in the full PRIORITY trial and other studies. The peptide-based diagnostic approach continues to advance toward clinical implementation.
- Original Title:
- Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.
- Published In:
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 29(8), 1563-70 (2014)
- Authors:
- Siwy, Justyna(4), Schanstra, Joost P(2), Argiles, Angel, Bakker, Stephan J L, Beige, Joachim, Boucek, Petr, Brand, Korbinian, Delles, Christian, Duranton, Flore, Fernandez-Fernandez, Beatriz, Jankowski, Marie-Luise, Al Khatib, Mohammad, Kunt, Thomas, Lajer, Maria, Lichtinghagen, Ralf, Lindhardt, Morten, Maahs, David M, Mischak, Harald, Mullen, William, Navis, Gerjan, Noutsou, Marina, Ortiz, Alberto, Persson, Frederik, Petrie, John R, Roob, Johannes M, Rossing, Peter, Ruggenenti, Piero, Rychlik, Ivan, Serra, Andreas L, Snell-Bergeon, Janet, Spasovski, Goce, Stojceva-Taneva, Olivera, Trillini, Matias, von der Leyen, Heiko, Winklhofer-Roob, Brigitte M, Zürbig, Petra, Jankowski, Joachim
- Database ID:
- RPEP-02504
Evidence Hierarchy
Frequently Asked Questions
How does this urine test detect kidney disease differently from standard tests?
Standard tests measure albumin (a single protein) in urine. CKD273 measures 273 specific peptide fragments simultaneously, creating a detailed molecular fingerprint of kidney health. This multi-peptide approach can detect kidney damage at earlier stages and with greater accuracy than albumin alone.
Is this test available to patients now?
CKD273 has been validated in research settings and is available through specialized proteomics laboratories in some countries, but it is not yet part of routine clinical practice in most healthcare systems. Ongoing trials and regulatory processes are working toward broader clinical implementation.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-02504APA
Siwy, Justyna; Schanstra, Joost P; Argiles, Angel; Bakker, Stephan J L; Beige, Joachim; Boucek, Petr; Brand, Korbinian; Delles, Christian; Duranton, Flore; Fernandez-Fernandez, Beatriz; Jankowski, Marie-Luise; Al Khatib, Mohammad; Kunt, Thomas; Lajer, Maria; Lichtinghagen, Ralf; Lindhardt, Morten; Maahs, David M; Mischak, Harald; Mullen, William; Navis, Gerjan; Noutsou, Marina; Ortiz, Alberto; Persson, Frederik; Petrie, John R; Roob, Johannes M; Rossing, Peter; Ruggenenti, Piero; Rychlik, Ivan; Serra, Andreas L; Snell-Bergeon, Janet; Spasovski, Goce; Stojceva-Taneva, Olivera; Trillini, Matias; von der Leyen, Heiko; Winklhofer-Roob, Brigitte M; Zürbig, Petra; Jankowski, Joachim. (2014). Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 29(8), 1563-70. https://doi.org/10.1093/ndt/gfu039
MLA
Siwy, Justyna, et al. "Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.." Nephrology, 2014. https://doi.org/10.1093/ndt/gfu039
RethinkPeptides
RethinkPeptides Research Database. "Multicentre prospective validation of a urinary peptidome-ba..." RPEP-02504. Retrieved from https://rethinkpeptides.com/research/siwy-2014-multicentre-prospective-validation-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.